Harrow (HROW) Income towards Parent Company (2010 - 2026)
Harrow (HROW) posted Income towards Parent Company of -$17.3 million for Q2 2026, up 37.43% on a QoQ basis from -$27.6 million in Q1 2026, and down 445.75% year-over-year from $5.0 million in Q2 2025.
Analysis
Harrow (HROW) Income towards Parent Company (2010 - 2026) Analysis & Trends
Harrow has reported Income towards Parent Company for 17 years, with the latest figure at -$17.3 million in Q2 2026.
- On a quarterly basis, Income towards Parent Company fell 445.75% year-over-year to -$17.3 million in Q2 2026; TTM through Jun 2026 was -$33.5 million, a 227.09% decrease from a year earlier, with the FY2025 full-year figure at -$5.1 million, up 70.6% from the prior year.
- Income towards Parent Company was -$17.3 million for Q2 2026 at Harrow, up from -$27.6 million in the prior quarter.
- The five-year high for Income towards Parent Company was $10.4 million in Q4 2025, with the low at -$27.6 million in Q1 2026.
- Average Income towards Parent Company over 5 years is -$5.7 million, with a median of -$5.3 million recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company tumbled 1223.5% in 2022, then jumped 177.17% in 2025.
- Over 5 years, Income towards Parent Company stood at $1.1 million in 2022, then sank by 967.11% to -$9.1 million in 2023, then soared by 174.08% to $6.8 million in 2024, then soared by 53.42% to $10.4 million in 2025, then plunged by 266.11% to -$17.3 million in 2026.
- The last three Income towards Parent Company figures came in at -$17.3 million (Q2 2026), -$27.6 million (Q1 2026), and $10.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 50.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.27 Mn |
| Mar 31, 2026 | -27.60 Mn |
| Dec 31, 2025 | 10.40 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -9.15 Mn |
| Sep 30, 2023 | -4.39 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -6.64 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -6.24 Mn |
| Mar 31, 2022 | -2.44 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.33 Mn |